Skip to main content
Erschienen in: Annals of Hematology 10/2016

27.07.2016 | Letter to the Editor

ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin

verfasst von: Muhammad Bilal Abid, Shi Wang, Hoi Yin Loi, L. M. Poon

Erschienen in: Annals of Hematology | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Literatur
1.
Zurück zum Zitat Gascoyne RD, Aoun P, Wu D et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMed Gascoyne RD, Aoun P, Wu D et al (1999) Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913–3921PubMed
2.
Zurück zum Zitat Savage KJ, Harris NL, Vose JM et al (2008) International peripheral T-cell lymphoma project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 111:5496–5504CrossRefPubMed Savage KJ, Harris NL, Vose JM et al (2008) International peripheral T-cell lymphoma project. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-cell Lymphoma Project. Blood 111:5496–5504CrossRefPubMed
3.
Zurück zum Zitat Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821CrossRefPubMed Younes A, Bartlett NL, Leonard JP et al (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–1821CrossRefPubMed
4.
Zurück zum Zitat Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196CrossRefPubMed Pro B, Advani R, Brice P et al (2012) Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190–2196CrossRefPubMed
5.
Zurück zum Zitat Chen X, Soma LA, Fromm JR (2013) Targeted therapy for hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther 7:45–56PubMedPubMedCentral Chen X, Soma LA, Fromm JR (2013) Targeted therapy for hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin. Onco Targets Ther 7:45–56PubMedPubMedCentral
6.
Zurück zum Zitat Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465CrossRefPubMed Francisco JA, Cerveny CG, Meyer DL et al (2003) cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 102:1458–1465CrossRefPubMed
Metadaten
Titel
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin
verfasst von
Muhammad Bilal Abid
Shi Wang
Hoi Yin Loi
L. M. Poon
Publikationsdatum
27.07.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 10/2016
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2746-3

Weitere Artikel der Ausgabe 10/2016

Annals of Hematology 10/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.